R&D Pipeline

Current Pipeline

Our Research


AJ302 is a first-in-class HDAC6 inhibitor under development for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy. Phase 1 clinical trial of AJ302 will be initiated in early 2021.


AJ303 is a novel compound under development for the treatment of idiopathic pulmonary fibrosis (IPF). It decreased IPF-related inflammatory cytokines, such as IL-6, MCP1, and GM-CSF in vitro, that delays the progression of pulmonary fibrosis in bleomycin-induced pulmonary injury model in mice. 


Coming Soon


Coming Soon

Scroll to Top